PR Newswire - Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA® and Asacol® for the Treatment of Ulcerative...
October 6, 2008 -- PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announced the results from a...
Business Wire - Low Levels of Diagnosis and New Biological Approaches to Treatment Indicate a Positive Future for Gastrointestinal Drugs
June 18, 2008 -- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/e40571/gastrointestinal_d) has announced the addition of the...
Emerging Infectious Diseases - Extensively drug-resistant tuberculosis, Lesotho
June 1, 2008 -- To the Editor: Reports of extensively drug-resistant tuberculosis (XDR TB) in the Republic of South Africa have generated concern in the medical and...
Business Wire - The Global Tuberculosis Strategies - Epidemiologic Statistics, Screening and Diagnostic, Therapeutics and Strategic Assessment of Tuberculosis Market Potential
June 14, 2007 -- LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its...
PR Newswire Europe - FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis.
January 17, 2007 -- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, January 16 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today...
PR Newswire UK Disclose - SHIRE PLC - FDA Approves LIALDA first once-daily mesalamine for UC.
January 17, 2007 -- FDA Approves LIALDAacents (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis...
Internal Medicine News - Sargramostim improves quality of life in patients with Crohn's
March 15, 2006 -- HONOLULU -- Sargramostim shows considerable promise as a novel treatment for Crohn's disease, Dr. Suzanne Laplante reported at the annual meeting of...
OB/GYN News - GI agents: Part II
February 15, 2006 -- The second part of this three-part series examines the safety of agents used to treat several gastrointestinal diseases that cause significant...
Internal Medicine News - Once-daily mesalamine stalls ulcerative colitis
December 15, 2005 -- HONOLULU -- A novel, once-daily high-strength formulation of 5-aminosalicylic acid proved effective for the induction of remission and other end...
Pediatric News - 5-ASA therapy can suppress Crohn's flares
May 1, 2005 -- PARIS -- Almost half (46%) of 1,013 children treated with 5-aminosalicylic acid only for 4 weeks after diagnosis with Crohn's disease had no disease...
